In addition, low levels of adropin have been proposed as a novel biomarker for HF, renal outcomes, type 2 DM-induced adverse cardiac remodeling, atherosclerosis and cardiac cachexia [37,38,39]. Here, ENHO is linked to atherosclerosis.